Blueprint Medicines (BPMC) Q4 2024 earnings summary

Executive summary

• AYVAKIT global net product revenues reached $479.0M in 2024, up 135% year-over-year, with $144.1M in Q4 2024, reflecting strong market adoption in systemic mastocytosis (SM).

• 2025 guidance for AYVAKIT net product revenue is $680M–$710M, targeting 45% year-over-year growth at midpoint and aiming for $2B by 2030.

• SM market opportunity revised upward to $4B peak value, driven by higher diagnosed prevalence and expanding provider base.

• Strategic investments in education, market-building, and commercial infrastructure to drive multidimensional growth.

• Focused on operational excellence, innovation, and advancing clinical programs for long-term growth.

Financial highlights

• Full-year 2024 revenues totaled $508.8M, with $479.0M from AYVAKIT and $29.9M from collaborations; Q4 revenue was $146.4M.

• Net loss for 2024 was $(67.1)M, improved from $(507.0)M in 2023, aided by a $173.7M debt extinguishment gain.

• Cash, cash equivalents, and investments stood at $863.9M at year-end 2024, up from $767.2M.

• Operating cash burn reduced by more than half in 2024; further decline expected in 2025.

• Cost of sales increased to $20.2M for 2024, reflecting higher product sales volume.

Outlook and guidance

• 2025 AYVAKIT revenue expected at $680M–$710M, with 45% year-over-year growth at midpoint and strong patient growth anticipated.

• International revenue expected to remain 10–15% of total, with additional European markets coming online in 2025.

• Long-term goal to reach $2B in AYVAKIT revenue by 2030, with further upside from broader SM franchise.

• Multiple clinical data milestones anticipated in 2025 and beyond, including BLU-808 proof-of-concept.

• Existing cash and anticipated revenues expected to support a self-sustainable financial profile.